Biseptol 480 (Co-trimoxazole) is used within therapeutic areas involving heightened responses and helps address symptom clusters that may become intense or disruptive.

---

Biseptol 480 is applied in therapeutic domains associated with symptomatic relief across acute therapeutic contexts. Specific conditions for which this medication is considered relevant include uncomplicated urinary tract infections (UTIs), acute exacerbation of chronic bronchitis, and certain enteric infections like Shigellosis. It is also applied in managing and preventing severe opportunistic infections such as Pneumocystis jirovecii pneumonia (PJP) and Toxoplasmosis. In these scenarios, the medication contributes to easing the overall symptom load by addressing pronounced symptoms like painful urination, fever, and acute diarrheal distress.

“The prophylactic use of this combination agent in vulnerable patient populations supports general well-being during symptomatic phases and assists with maintaining functional stability.”

Quick Fact: Supports Symptomatic Management for Genitourinary Distress and Systemic Fever.

Eligibility Scope

The eligibility for Biseptol 480 (Co-trimoxazole) is strictly governed by regulatory criteria, which define both absolute exclusions and conditional use requirements.

Category	Official Regulatory Statement
Populations for whom use is allowed	Pediatric patients 2 months of age and older, and adults/adolescents who do not present with any contraindicating condition.
Populations for whom use is contraindicated	Patients with known hypersensitivity to sulfonamides or trimethoprim; infants less than 2 months of age; pregnant patients at term; nursing mothers.
Age-related eligibility rules	Minimum Age: Contraindicated for all pediatric patients less than 2 months of age. Older Adults: Use requires particular care due to increased susceptibility to adverse reactions.
Condition-specific eligibility rules	Severe Organ Damage: Contraindicated in marked hepatic damage or severe renal insufficiency (Creatinine Clearance <15 mL/min).
Pregnancy and lactation eligibility status	Pregnancy: Contraindicated at term. Lactation: Contraindicated in nursing mothers.

Eligibility-Related Restrictions

• The medicine is contraindicated in patients with documented megaloblastic anemia due to folate deficiency and those with drug-induced immune thrombocytopenia.
• Patients with moderate renal impairment ( CrCl 15 to 30 mL/min) are eligible but are classified as restricted use, requiring a mandatory 50% dose reduction.
• Caution is required for patients with Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency or those with pre-existing folate deficiency.

Connection to the Overall Eligibility Profile

Official regulatory documents define who may use Biseptol 480 through specific absolute contraindications based on age, hypersensitivity, and severe organ dysfunction. Eligibility for other populations is conditional, requiring mandatory restrictions and caution in the presence of metabolic disorders like G-6-PD deficiency or pre-existing folate deficiency.

Interactions with other medicines and products

Biseptol 480 (Co-trimoxazole) interactions are officially documented across several categories, primarily involving altered plasma concentrations of co-administered drugs or additive physiological risks.

Formal Contraindications and Major Restrictions

Strict regulatory contraindications prohibit co-administration with certain agents. The combination of Co-trimoxazole and Dofetilide is forbidden due to the potential for significantly increased Dofetilide plasma levels, which raises the risk of severe cardiac arrhythmias. Furthermore, high-dose adjunctive use of Methotrexate for Pneumocystis jirovecii pneumonia (PJP) is restricted by some authorities due to increased mortality risk.

Significant Pharmacokinetic Interactions

Co-trimoxazole is documented to affect the clearance of several medicines. It enhances the anticoagulant effect of Warfarin through both metabolic inhibition and protein binding displacement, requiring close monitoring. It also prolongs the half-life of Phenytoin, leading to increased exposure. Trimethoprim, a component, is noted to significantly increase the plasma levels of Lamivudine and the antidiabetic agent Repaglinide via interference with renal excretion.

Pharmacodynamic and Other Additive Effects

Co-administration with agents that increase serum potassium, such as ACE Inhibitors, ARBs, or potassium-sparing diuretics (e.g., Spironolactone), may result in clinically relevant hyperkalaemia due to an additive effect. Concurrent use with anti-folate agents like high-dose Pyrimethamine may lead to megaloblastic anaemia. In elderly patients, co-administration with thiazide diuretics increases the risk of thrombocytopenia.

The action of Biseptol 480 (Co-trimoxazole) is defined by its selective action against the bacterial process of synthesizing folic acid (folate), an obligate pathway for bacterial growth. The dual components target two separate, sequential enzymatic steps within this pathway.

Molecular Targeting of Two Sequential Enzymes

The drug employs a sequential blockade strategy that targets two distinct enzymes: dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR). Sulfamethoxazole acts first by competitively inhibiting DHPS, while Trimethoprim follows by selectively inhibiting DHFR. The dual blockade ensures the inhibition of both the initial precursor production and the final activation step of folate synthesis, a metabolic function absent in human cells.

Arrest of Bacterial DNA Synthesis and Replication

By halting the creation of active tetrahydrofolate (THF), the drug starves the bacteria of the necessary coenzyme for producing purines and pyrimidines—the fundamental building blocks of their DNA and RNA. This molecular cascade leads to the complete arrest of cellular replication and genetic repair. The resulting physiological effect is synergistic potentiation, which causes cellular death of the susceptible microorganisms, classifying the action as bactericidal.

How to Use Biseptol 480: General Administration Guidelines

Biseptol 480 (Co-trimoxazole) is administered systemically through two main routes: oral (tablet or suspension) or intravenous (IV) infusion. The core principle of its use is the delivery of the combined active agents, Sulfamethoxazole (SMX) and Trimethoprim (TMP), in a fixed ratio of 5:1, typically as a unit containing 800 mg SMX and 160 mg TMP for the standard adult dose.

---

Dosing and Scheduling

Feature	General Administration Details
Standard Frequency	Twice daily (every 12 hours) for most acute infections.
High-Dose Regimen	For specialized use, doses are based on the TMP component, administered in three or four divided doses daily.
Administration Timing	Oral forms may be taken with or without food, but administration with food can help minimize gastrointestinal upset.
Course Duration	Ranges from a short-term minimum of 5 days for certain acute infections to long-term, intermittent cycles for prophylaxis.

---

Procedural Requirements

Standard guidelines define specific conditions for administration. Oral doses must be taken with plenty of liquid (a full glass of water) to ensure proper intake. For the intravenous route, the solution must be diluted immediately prior to use and administered as a slow infusion over a period of 60 to 90 minutes.

Furthermore, dosage requires adjustment in specific populations: for renal impairment, a dose reduction (often to 50%) is necessary when Creatinine Clearance is between 15 and 30 mL/min. Pediatric dosing is strictly weight-based, calculated using the Trimethoprim component.

Research Evidence / Overview of Studies for Biseptol 480

This overview describes the official research evidence for Biseptol 480 (Co-trimoxazole), focusing on the types of studies conducted, the populations included, and the outcomes that researchers monitored. This section highlights what is known about the study structure and what remains uncertain, providing context but not individual predictions or medical advice.

---

Evidence for Treating Acute Bacterial Infections (UTIs, AECB, and Enteric)

Research has explored the use of Biseptol 480 for acute bacterial infections through both short-term randomized controlled trials (RCTs) and systematic reviews. These studies examined conditions where symptoms may vary in intensity, such as uncomplicated urinary tract infections (UTIs) and exacerbations of chronic bronchitis (AECB). Researchers monitored outcomes related to physical discomfort, such as changes in discomfort or frequency, and specifically monitoring the rate of measured reduction in bacteria count.

For acute UTIs, findings from comparative trials often described patterns concerning the measured reduction in bacteria count. However, the evidence is limited in that its reliability may depend on local patterns of bacterial resistance, which is an ongoing area of surveillance. For some enteric infections, evidence suggests a diminished relevance of the evidence for current empirical use due to the documented pattern of high resistance across common bacterial strains.

---

Evidence for Prophylaxis in Immunocompromised Populations

A significant body of research, including large-scale RCTs and long-term cohort studies, has been conducted in immunocompromised individuals. This research examined the use of Biseptol 480 in studying the rate of occurrence of opportunistic infections, notably Pneumocystis jirovecii pneumonia (PJP).

The studies explored the drug's use in settings involving patients with systemic imbalance and monitored several key outcomes. Researchers tracked the incidence rate of PJP, the study outcome of all-cause mortality, and the occurrence of other opportunistic diseases. Findings from these long-term studies described patterns concerning the measured incidence of PJP and changes in disease markers in the monitored populations.

---

Key Limitations and Areas of Uncertainty

Limitations noted in the research include that results apply only to the populations studied, and follow-up durations were limited in many of the trials for acute infections. A significant area of uncertainty relates to the global increase in bacterial resistance. Surveillance studies have observed patterns of high resistance prevalence, and research is ongoing to understand the long-term impact on the selection of resistant organisms. The certainty of evidence remains low for regions where local resistance is high, and comparative evidence is lacking in many contemporary settings.

Key Studies & References Sulfamethoxazole/Trimethoprim (Co-trimoxazole) Prescribing Information (DailyMed)

Common questions about Biseptol 480 (FAQ)

Q: Can pregnant women safely take Biseptol 480 during any trimester?

Official prescribing information advises that this medication may cause harm to a fetus. It is generally not recommended during pregnancy and is specifically contraindicated near term due to the risk of kernicterus (severe jaundice) in the newborn. Prescribing information states that the drug is considered for use only when the potential benefit is judged to outweigh the potential risk to the fetus.

Q: What are the signs that Biseptol 480 might not be working for an infection?

As an antibacterial agent, Biseptol 480 is intended to eliminate susceptible bacteria. Failure of symptoms to improve or a worsening of the condition after treatment begins can indicate that the underlying infection is resistant to the drug or is due to another type of pathogen. Official guidance notes that the drug is intended for proven bacterial infections and that the entire prescribed course of treatment must be taken.

Q: Is it common for Biseptol 480 to cause changes in taste or appetite?

Official adverse reaction data indicates that loss of appetite, or anorexia, is listed as a common side effect of Biseptol 480. Additionally, changes in taste, known as dysgeusia, have been reported in some post-marketing surveillance or clinical experience reports.

Q: Are there any specific supplements or vitamins that should be avoided while on Biseptol 480?

Because Biseptol 480 interferes with the way bacteria make folic acid, there is potential for interaction with other anti-folate agents. Official information also notes that the component Trimethoprim may reduce serum Vitamin A levels. Any decision regarding folic acid supplementation should be made in consultation with a healthcare professional.

Q: What is the general duration of treatment with Biseptol 480 for a standard infection?

The official duration of treatment varies depending on the specific type and severity of the infection being treated. For common acute issues, such as a severe urinary tract infection, the course is typically 14 days. For other specific infections like Shigellosis, a shorter course of 5 days is often prescribed.

Q: Does Biseptol 480 interact with common pain relievers like Ibuprofen or Paracetamol?

Formal interaction studies for common over-the-counter pain relievers like Ibuprofen or Paracetamol are not specifically detailed in regulatory documents. However, official information does advise caution when Biseptol 480 is used with other medications that can increase potassium levels, as this combination may heighten the risk of hyperkalemia (high potassium).

Q: What is the risk of developing Clostridium difficile infection after taking Biseptol 480?

Like nearly all antibiotics, Biseptol 480 can disrupt the natural balance of beneficial bacteria in the colon, which may allow the overgrowth of Clostridium difficile (C. difficile). This can result in C. difficile-Associated Diarrhea (CDAD). This severe form of diarrhea can occur during treatment or up to two months after stopping the medication.

Q: Does Biseptol 480 have any effect on the normal gut flora (good bacteria)?

Yes, official labeling indicates that as an antibacterial agent, Biseptol 480 alters the normal flora (natural community of microorganisms) of the colon. This change in the gut environment is the underlying reason for the potential risk of subsequent infections, such as overgrowth of C. difficile.

Q: What should I do if I miss a scheduled dose of Biseptol 480?

Patient counseling information advises taking a missed dose as soon as it is remembered. However, if the interval until the next dose is short, patient information advises that the missed dose should be skipped and the regular dosing schedule resumed. Regulatory instructions indicate that the prescribed dosing schedule should be maintained as closely as possible.

Q: Why is Biseptol 480 sometimes prescribed in different strengths, even though it's called '480'?

The name 'Biseptol 480' typically refers to the standard-strength tablet (400 mg Sulfamethoxazole and 80 mg Trimethoprim). However, the active ingredient combination (Co-trimoxazole) is also officially available in other strengths, such as a double-strength tablet (often 800 mg Sulfamethoxazole and 160 mg Trimethoprim), as well as liquid suspensions and intravenous solutions.

Q: What is the reason Biseptol 480 is sometimes used to treat 'traveler's diarrhea'?

Official indications for Biseptol 480 include the treatment of Traveler's Diarrhea. This use is specifically for cases caused by susceptible strains of the bacterium Escherichia coli (E. coli). The drug's broad antibacterial action allows it to target this common cause of the condition.

Q: Can Biseptol 480 cause any changes to one's mood or sleeping patterns?

While not among the most common effects, regulatory adverse reaction data includes reports of effects on the central nervous system. These documented reactions include rare cases of insomnia (trouble sleeping), depression, and hallucinations.

Q: Can Biseptol 480 affect the effectiveness of oral birth control pills?

Regulatory documents indicate that Biseptol 480 can affect the metabolism of certain other medicines. Due to the potential for interactions, official information suggests that patients using oral contraceptives should consult with a healthcare professional regarding the need for alternative or additional contraceptive measures while on this medication.

Storage and Disposal of Biseptol 480 (Co-trimoxazole) Tablets

The storage of Biseptol 480 (sulfamethoxazole and trimethoprim) tablets must comply strictly with regulatory requirements to preserve the drug's stability. The official labeling mandates storage at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F), with temporary excursions allowed up to 30 C.

Storage Requirement	Classification
Temperature	Controlled Room Temperature (20 C–25 C)
Protection	Keep in original, tightly closed container; Protect from moisture and light
Safety	Keep out of the sight and reach of children

For disposal, unused or expired Biseptol 480 must be handled according to local official regulations. The drug should not be discarded in wastewater or household trash unless directed by the regulator. If a drug take-back program is unavailable, non-flushable medicines may be mixed with an undesirable substance (such as dirt or used coffee grounds) and sealed in a bag before being placed in the trash.